Please use this link to access this publication. Abstract Cannabis use in cancer care is increasingly common for symptom management, but emerging studies suggest potential interactions with immunotherapy that may reduce treatment efficacy. This review explores findings from recent studies, highlights the need for cautious interpretation and discusses the appropriateness of medicinal cannabis use during cancer immunotherapy. While three key studies (Taha et al., 2019; Bar-Sela et al., 2020; Hadid et al., 2024) observed lower response rates and reduced survival in patients using cannabis alongside immunotherapy, methodological concerns and demographic differences raise questions about their findings. Critiques by Piper et al. emphasise the need...